A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache
Sponsor study identifier
interventional
2
1 country
6
Study Start
August 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2004
Actual (reported)Study Completion
January 2004
Actual (reported)This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2004
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2003
Date type not reportedThis date has not been verified as actual or estimated.
September 15, 2003
Actual (reported)September 16, 2003
Actual (reported)January 2004
Actual (reported)January 2004
Actual (reported)Nasal Solution 0.01%
Placebo nasal solution with sodium chloride 10%
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
San Francisco Clinical Research Center
San Francisco, California, United States
California Medical Clinic for Headache
Santa Monica, California, United States
Colorado Neurology and Headache Clinic
Denver, Colorado, 80218, United States
Diamond Headache Clinic
Chicago, Illinois, United States
New York Headache Center
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Scott B Phillips, MD
Winston Laboratories
2 participants (actual enrollment reported by the registry).
First Submitted
September 15, 2003
First Posted
September 16, 2003
Study Start
August 2003
Date type not reportedThis date has not been verified as actual or estimated.
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
Primary Completion
January 2004
Actual (reported)Study Completion
January 2004
Actual (reported)Last Updated
June 10, 2011
Record last verified: 2011-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: